Metalloproteinase 11, potential marker and molecular target in advanced and castration-resistant prostate cancer. Culture study of peritumoral fibroblasts.
OBJECTIVE
To analyze the expression of metalloprotein 11 (MMP11) in cultured fibroblasts obtained from human prostate tumors with different clinical and pathological characteristics.


METHODS
For this study we analyzed samples of transrectal prostate biopsies from tumors with different characteristics, treated with or whithout androgen deprivation (AD). After optimization of the culture method, fibroblasts were isolated and cultured to perform the study (PCR) of MMP11 mRNA.


RESULTS
Finally, 37 cases were studied: 5 samples of benign prostatic hyperplasia, 14 cases with localized neoplasms (7 high-risk according to the D'Amico classification), 5 with metastasic tumors (bone metastases), and 13 treated with AD therapy, of which 6 fulfilled the requirements to be defined as resistant to castration. In tumors without AD therapy, MMP11 expression was significantly higher (P=.001) in fibroblasts of higher grade tumors. A significant (P=.001) correlation was found between PSA and expression of MMP11 in fibroblast s and a significant increase of MMP11 expression in metastatic tumors. In tumors with AD therapy, a significantly greater expression of MMP11 was observed in resistant to castration patients than in those sensitive to castration (P=.003).


CONCLUSIONS
In advanced prostate tumors or in stages of increased tumor aggressiveness, the production of MMP11 by fibroblasts is significantly greater than in non-metastatic tumors or in AD sensitive tumors.
Servicio de Urología, Hospital Central de Asturias, Oviedo, Asturias, España. Electronic address: jmfergomez@gmail.com.
J M
JM
Fernandez-Gomez
Investigadora, Unidad de Investigación, Fundación Hospital de Jove, Gijón, Asturias, España.
N
N
Eiro
Servicio de Urología, Hospital Central de Asturias, Oviedo, Asturias, España.
J J
JJ
García-Rodríguez
Servicio de Urología, Hospital Central de Asturias, Oviedo, Asturias, España.
A
A
Quintás-Blanco
Servicio de Urología, Hospital Central de Asturias, Oviedo, Asturias, España.
C
C
Gonzalez-Ruiz de León
Servicio de Urología, Hospital Central de Asturias, Oviedo, Asturias, España.
M L
ML
Perez de Haro
Jefe de la Unidad de Investigación, Fundación Hospital de Jove, Gijón, Asturias, España.
F
F
Vizoso-Piñero
D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis; D000072645:Cancer-Associated Fibroblasts / Q000378:metabolism*; D002478:Cells, Cultured; D006801:Humans; D008297:Male; D053507:Matrix Metalloproteinase 11 / Q000096:biosynthesis*; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology* / Q000628:therapy
D014408:Biomarkers, Tumor; D053507:Matrix Metalloproteinase 11
Cell cultures; Cultivo celular; Cáncer de próstata; Estroma; Metalloproteinases; Metaloproteinasas; Prostate cancer; Stroma